The validation of new CHD1L inhibitors as a therapeutic strategy for cancer.
Clune S, Awolade P, Zhou Q, Esquer H, Matter B, Kearns JT, Kellett T, Akintayo DC, Kompella UB, LaBarbera DV.
Clune S, et al. Among authors: labarbera dv.
Biomed Pharmacother. 2024 Jan;170:116037. doi: 10.1016/j.biopha.2023.116037. Epub 2023 Dec 20.
Biomed Pharmacother. 2024.
PMID: 38128184
Free PMC article.